title: In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients.
abstract: The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.
authors.affiliation: Institute of Infectious Diseases and Public Health, Università Politecnica dell Marche, Ancona, Italy. anconacmi@interfree.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kamysz
authors.forename: Giuseppina
authors.initials: G
authors.lastname: D'Amato
authors.forename: Carmela
authors.initials: C
authors.lastname: Silvestri
authors.forename: Maria Simona
authors.initials: MS
authors.lastname: Del Prete
authors.forename: Alberto
authors.initials: A
authors.lastname: Licci
authors.forename: Alessandra
authors.initials: A
authors.lastname: Riva
authors.forename: Jerzy
authors.initials: J
authors.lastname: Lukasiak
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
mesh_terms: D024901:Drug Resistance, Multiple, Bacterial; D054808:Histatins; D006801:Humans; D016867:Immunocompromised Host; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012471:Salivary Proteins and Peptides / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*
chemical_list: D054808:Histatins; C488466:P-113D; D012471:Salivary Proteins and Peptides
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8856-61
references.pmid: 10922046
references.citation: Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23
references.pmid: 10348745
references.citation: Antimicrob Agents Chemother. 2001 Dec;45(12):3437-44
references.pmid: 11709321
references.citation: Lancet Infect Dis. 2001 Oct;1(3):156-64
references.pmid: 11871492
references.citation: Clin Microbiol Rev. 2002 Apr;15(2):194-222
references.pmid: 11932230
references.citation: Med Hypotheses. 2004;62(3):367-74
references.pmid: 14975505
references.citation: MMWR Recomm Rep. 2004 Mar 26;53(RR-3):1-36
references.pmid: 15048056
references.citation: J Infect Dis. 2004 Jul 15;190(2):356-64
references.pmid: 15216473
references.citation: Nature. 1987 Aug 6-12;328(6130):478
references.pmid: 3614352
references.citation: J Biol Chem. 1988 Jun 5;263(16):7472-7
references.pmid: 3286634
references.citation: Int J Pept Protein Res. 1990 Mar;35(3):161-214
references.pmid: 2191922
references.citation: J Antimicrob Chemother. 1993 Jun;31(6):919-26
references.pmid: 8360129
references.citation: Experientia. 1993 Dec 15;49(12):1095-7
references.pmid: 8270032
references.citation: Clin Infect Dis. 1998 May;26(5):1182-7
references.pmid: 9597250
references.citation: Crit Rev Oral Biol Med. 1998;9(4):480-97
references.pmid: 9825223
references.citation: Respiration. 1999;66(2):95-109
references.pmid: 10202312
references.citation: Antimicrob Agents Chemother. 1999 Jun;43(6):1379-82
references.pmid: 10348756
references.citation: Antimicrob Agents Chemother. 2001 May;45(5):1367-73
references.pmid: 11302797